We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIAZYME LABORATORIES

Diazyme develops diagnostic reagents using its proprietary enzyme technologies that can be used on most automated che... read more Featured Products: More products

Download Mobile App





Newly Launched Coronavirus Blood Test Identifies Past Exposure

By LabMedica International staff writers
Posted on 20 Apr 2020
A pair of new serological tests can detect novel coronavirus antibodies — evidence in persons tested that they have previously been infected by SARS-CoV-2, the viral cause of COVID-19 — even if they never experienced tell-tale symptoms. More...
The tests, developed by clinical laboratory physicians and scientists at UC San Diego (La Jolla, CA, USA), builds upon two assays developed by Diazyme Laboratories, Inc. (Poway, CA, USA).

The presence of novel coronavirus antibodies can reveal persons who may have unknowingly contracted COVID-19 and recovered, but never showed signs of infection. The tests analyze blood samples, similar to those taken for routine clinical reasons, for the presence of two of the body’s five classes of antibodies: IgG and IgM. Antibodies are proteins used by the immune system to recognize and help neutralize pathogenic invaders, such as viruses or bacteria. The IgG antibody is the most abundant type; IgM is one of the first antibody types produced by the body’s immune system to fight a new infection. Looking for these two types of antibodies together, rather than one, increases the treating physician’s confidence in being able to differentiate between a recent infection versus a past exposure to the SARS-CoV-2 virus.

The twin Diazyme tests have shown high sensitivity and specificity, particularly compared to most point-of-care, rapid-response serological tests for novel coronavirus now flooding the international market. So far, only one rapid serological test, which claims a result within 15 to 20 minutes, has received Emergency Use Authorization from the US Food and Drug Administration (FDA).

The coronavirus blood testing program at UC San Diego Health is, for now, open-ended and will be overseen by the UC San Diego Center for Advanced Laboratory Medicine (CALM), which houses the majority of UC San Diego Health’s Clinical Laboratories and related research activities and is already the hub for the health system’s in-house PCR-based diagnostic testing of patients and persons suspected of having COVID-19. The initial capacity for serological testing will be a combination of up to 1,200 of IgM or IgG antibody tests per day, with results within 24 hours and the system being scalable.

The first testing cohort will likely be health care workers, which will help identify who are now in a convalescent phase after a documented exposure and, perhaps, may have acquired at least some degree of immunological protection. At this point, it has not been established whether the presence of IgG antibodies is an indicator of immunity to SARS-CoV-2 infection or re-infection, as seen with many other viral infectious diseases. Aside from identifying past coronavirus exposure, serological testing will likely be a valuable epidemiological tool. There are expansive plans to use blood tests to map where the virus has spread, which cities, states and regions may have developed some degree of “herd immunity” to future outbreaks and which places and populations remain at greatest risk.

“These tests have already gone through an initial assessment and validation by Diazyme,” said Robert Fitzgerald, PhD, professor of clinical pathology at UC San Diego School of Medicine and director of the Toxicology Laboratory and associate director of Clinical Chemistry Laboratory at UC San Diego Health. “We’ve put them through our validation processes as well, including comparing samples from patients known to have COVID-19, healthy volunteers and blood samples from 2018, long before the virus appeared.”

“This is part of the next wave of testing,” said Ronald W. McLawhon, MD, PhD, director of CALM and UC San Diego Clinical Laboratories and chief of the Division of Laboratory and Genomic Medicine. “It’s intended to answer those growing questions about who has been infected and who might still be vulnerable to exposure.”



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Thyroid-Stimulating Hormone Test
ULTRA-TSH
New
Gold Member
Latex Test
SLE-Latex Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.